门内跨管大动脉替换的四步框架,用于未成功的手术和跨管大动脉生物假体
Milos Brankovic1, Hassan Akram2, Aisha Shabbir2
1Cardiovascular Division, Department of Medicine, University of Minnesota, Minneapolis, MN 55455, USA.
Reviews in cardiovascular medicine
|October 15, 2025
概括
现在,通过导管的动脉置换 (TAVR) 已用于内 (ViV) 程序,以治疗缺陷的生物假体. 本综述为ViV环境中规划TAVR提供了一个框架,改善患者的治疗结果.
科学领域:
- 心脏病学 心脏病学
- 干预心脏病学 干预心脏病学
- 生物医学工程 生物医学工程
背景情况:
- 超导管大动脉置换 (TAVR) 正在扩大,超越原生门疾病,进入门内 (ViV) 程序.
- ViV TAVR解决了手术 (TAV-in-SAV) 和先前透气管 (TAV-in-TAV) 生物假体的功能障碍.
- 在ViV技术的进步旨在克服诸如血动力学和冠状动脉阻塞等挑战.
研究的目的:
- 在ViV环境中审查支持TAVR的当前临床数据.
- 为 ViV TAVR. 程序规划提供一个结构化,四步框架.
- 综合临床应用的证据,指导心脏团队和患者咨询.
主要方法:
- 对TAVR用于生物假体门功能障碍的当前临床数据的审查.
- 制定一个由四个步骤组成的程序规划框架.
- 综合证据用于临床决策.
主要成果:
- 在ViV环境中,TAVR是管理生物假体门功能障碍的可行选择.
- 提出了一个四步框架 (风险评估,故障模式识别,植入策略,损伤评估).
- 目前的证据支持精细的ViV技术来改善结果.
结论:
- 在ViV设置中的TAVR越来越多地被用于生物假体门故障.
- 拟议的框架有助于优化程序规划和患者选择.
- 本综述为管理ViV TAVR病例的临床医生提供了可操作的见解.
相关概念视频
Mitral Stenosis III: Medical Management
246
Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
246
Aortic Regurgitation III: Medical Management
396
Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
396


